ACS Combinatorial Science最新文献

筛选
英文 中文
Reply to: "Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization". 答复"开始旅程:通过孟德尔随机化了解补体蛋白在肝脏疾病中的作用"。
IF 8.9 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-19 DOI: 10.3350/cmh.2024.0266
Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
{"title":"Reply to: \"Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization\".","authors":"Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu","doi":"10.3350/cmh.2024.0266","DOIUrl":"https://doi.org/10.3350/cmh.2024.0266","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":" 3","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140683325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer 上皮性卵巢癌非选择性多基因种系和体细胞基因检测的成本效益
IF 13.4 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-18 DOI: 10.6004/jnccn.2023.7331
R. Manchanda, Li Sun, Monika Sobocan, Isabel V Rodriguez, Xia Wei, A. Kalra, S. Oxley, Michail Sideris, C. Fierheller, Robert D. Morgan, D. Chandrasekaran, Kelly Rust, P. Spiliopoulou, Rowan E. Miller, Shanthini M. Crusz, Michelle Lockley, Naveena Singh, A. Faruqi, Laura Casey, E. Brockbank, Saurabh Phadnis, T. Mills-Baldock, Fatima El-Khouly, L. Jenkins, A. Wallace, Munaza Ahmed, Ajith Kumar, Elizabeth M. Swisher, C. Gourley, B. Norquist, D. G. Evans, R. Legood
{"title":"Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer","authors":"R. Manchanda, Li Sun, Monika Sobocan, Isabel V Rodriguez, Xia Wei, A. Kalra, S. Oxley, Michail Sideris, C. Fierheller, Robert D. Morgan, D. Chandrasekaran, Kelly Rust, P. Spiliopoulou, Rowan E. Miller, Shanthini M. Crusz, Michelle Lockley, Naveena Singh, A. Faruqi, Laura Casey, E. Brockbank, Saurabh Phadnis, T. Mills-Baldock, Fatima El-Khouly, L. Jenkins, A. Wallace, Munaza Ahmed, Ajith Kumar, Elizabeth M. Swisher, C. Gourley, B. Norquist, D. G. Evans, R. Legood","doi":"10.6004/jnccn.2023.7331","DOIUrl":"https://doi.org/10.6004/jnccn.2023.7331","url":null,"abstract":"Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)–based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone. Methods: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing (strategy B). Unaffected relatives with germline BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 PVs identified through cascade testing underwent appropriate OC and breast cancer (BC) risk-reduction interventions. We also compared the cost-effectiveness of multigene panel germline testing alone (without PARPi therapy) versus strategy B. Unaffected relatives with PVs could undergo risk-reducing interventions. Lifetime horizon with payer/societal perspectives, along with probabilistic/one-way sensitivity analyses, are presented. Incremental cost-effectiveness ratio (ICER) and incremental cost per quality-adjusted life year (QALY) gained were compared with £30,000/QALY (UK) and $100,000/QALY (US) thresholds. OC incidence, BC incidence, and prevented deaths were estimated. Results: Compared with clinical criteria/FH-based BRCA testing, BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 germline testing and BRCA1/BRCA2 somatic testing of all patients with OC incorporating PARPi therapy had a UK ICER of £51,175/QALY (payer perspective) and £50,202/QALY (societal perspective) and a US ICER of $175,232/QALY (payer perspective) and $174,667/QALY (societal perspective), above UK/NICE and US cost-effectiveness thresholds in the base case. However, strategy A becomes cost-effective if PARPi costs decrease by 45% to 46% or if overall survival with PARPi reaches a hazard ratio of 0.28. Unselected panel germline testing alone (without PARPi therapy) is cost-effective, with payer-perspective ICERs of £11,291/QALY or $68,808/QALY and societal-perspective ICERs of £6,923/QALY or $65,786/QALY. One year’s testing could prevent 209 UK BC/OC cases and 192 deaths, and 560 US BC/OC cases and 460 deaths. Conclusions: Unselected panel germline and somatic BRCA testing can become cost-effective, with a 45% to 46% reduction in PARPi costs. Regarding germline testing, unselected panel germline testing is highly cost-effective and should replace BRCA testing alone.","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":" 11","pages":""},"PeriodicalIF":13.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140687055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Author Correction: Interacting topological quantum chemistry in 2D with many-body real space invariants 作者更正:二维拓扑量子化学与多体真实空间不变式的相互作用
IF 16.6 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-17 DOI: 10.1038/s41467-024-47165-z
Jonah Herzog-Arbeitman, B. Bernevig, Zhi-da Song
{"title":"Author Correction: Interacting topological quantum chemistry in 2D with many-body real space invariants","authors":"Jonah Herzog-Arbeitman, B. Bernevig, Zhi-da Song","doi":"10.1038/s41467-024-47165-z","DOIUrl":"https://doi.org/10.1038/s41467-024-47165-z","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"125 6","pages":""},"PeriodicalIF":16.6,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome. 氯吡格雷单药治疗双重风险急性冠状动脉综合征
IF 24 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-17 DOI: 10.1001/jamacardio.2024.0547
Marco Valgimigli, A. Landi
{"title":"Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome.","authors":"Marco Valgimigli, A. Landi","doi":"10.1001/jamacardio.2024.0547","DOIUrl":"https://doi.org/10.1001/jamacardio.2024.0547","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"164 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. 急性冠状动脉综合征高缺血和出血风险患者的延长氯吡格雷单药治疗与 DAPT:OPT-BIRISK 随机临床试验。
IF 24 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-17 DOI: 10.1001/jamacardio.2024.0534
Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, M. Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W. Stone, D. Angiolillo, Yaling Han
{"title":"Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.","authors":"Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, M. Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W. Stone, D. Angiolillo, Yaling Han","doi":"10.1001/jamacardio.2024.0534","DOIUrl":"https://doi.org/10.1001/jamacardio.2024.0534","url":null,"abstract":"Importance\u0000Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).\u0000\u0000\u0000Objective\u0000To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).\u0000\u0000\u0000Design, Setting, and Participants\u0000This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months at 101 China centers between February 2018 and December 2020. Study data were analyzed from April 2023 to May 2023.\u0000\u0000\u0000Interventions\u0000Patients were randomized either to clopidogrel plus placebo or clopidogrel plus aspirin for an additional 9 months.\u0000\u0000\u0000Main Outcomes and Measures\u0000The primary end point was Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). The primary end point was tested for superiority, and the MACCE end point was tested for sequential noninferiority and superiority.\u0000\u0000\u0000Results\u0000A total of 7758 patients (mean [SD] age, 64.8 [9.0] years; 4575 male [59.0%]) were included in this study. The primary end point of BARC types 2, 3, or 5 bleeding occurred in 95 of 3873 patients (2.5%) assigned to clopidogrel plus placebo and 127 of 3885 patients (3.3%) assigned to clopidogrel plus aspirin (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; difference, -0.8%; 95% CI, -1.6% to -0.1%; P = .03). The incidence of MACCE was 2.6% (101 of 3873 patients) in the clopidogrel plus placebo group and 3.5% (136 of 3885 patients) in the clopidogrel plus aspirin group (HR, 0.74; 95% CI, 0.57-0.96; difference, -0.9%; 95% CI, -1.7% to -0.1%; P < .001 for noninferiority; P = .02 for superiority).\u0000\u0000\u0000Conclusions and Relevance\u0000Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.\u0000\u0000\u0000Trial Registration\u0000ClinicalTrials.gov Identifier: NCT03431142.","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":" 28","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140692839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Author Correction: Direct observation of a crescent-shape chromosome in expanded Bacillus subtilis cells 作者更正:直接观察膨大枯草杆菌细胞中的新月形染色体
IF 16.6 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-16 DOI: 10.1038/s41467-024-47723-5
M. Tišma, F. P. Bock, Jacob W. J. Kerssemakers, Hammam Antar, A. Japaridze, S. Gruber, C. Dekker
{"title":"Author Correction: Direct observation of a crescent-shape chromosome in expanded Bacillus subtilis cells","authors":"M. Tišma, F. P. Bock, Jacob W. J. Kerssemakers, Hammam Antar, A. Japaridze, S. Gruber, C. Dekker","doi":"10.1038/s41467-024-47723-5","DOIUrl":"https://doi.org/10.1038/s41467-024-47723-5","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"24 24","pages":""},"PeriodicalIF":16.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. 运动、饮食和/或药物干预对超重或肥胖育龄妇女的体重指数、排卵和荷尔蒙状况的比较效果:系统综述和网络荟萃分析。
IF 13.3 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-16 DOI: 10.1093/humupd/dmae008
D. Ruiz-González, I. Cavero-Redondo, A. Hernández-Martínez, Andrés Baena-Raya, S. Martínez-Forte, S. Altmäe, Ana M Fernández-Alonso, A. Soriano‐Maldonado
{"title":"Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis.","authors":"D. Ruiz-González, I. Cavero-Redondo, A. Hernández-Martínez, Andrés Baena-Raya, S. Martínez-Forte, S. Altmäe, Ana M Fernández-Alonso, A. Soriano‐Maldonado","doi":"10.1093/humupd/dmae008","DOIUrl":"https://doi.org/10.1093/humupd/dmae008","url":null,"abstract":"BACKGROUND\u0000The increasing prevalence of obesity worldwide poses a significant threat to reproductive function owing, in part, to hormonal disturbances caused by negative feedback between excess adiposity and the hypothalamic-pituitary-ovarian axis. Consequently, finding the most appropriate strategies to lose weight and improve ovulation in women with overweight or obesity is a clinically relevant matter that needs to be investigated. A comprehensive comparison of the independent and combined efficacy of lifestyle and/or pharmacological interventions on BMI, ovulation, and hormonal profile in women with overweight or obesity at risk of anovulatory infertility would facilitate improving fertility strategies in this population.\u0000\u0000\u0000OBJECTIVE AND RATIONALE\u0000This study aimed to evaluate the comparative efficacy of exercise, diet, and pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity.\u0000\u0000\u0000SEARCH METHODS\u0000A systematic review was performed by searching PubMed, Scopus, Web of Science, PsycINFO, and Cochrane Library up to 14 December 2023, for randomized controlled trials assessing the effects of exercise, diet and/or pharmacological interventions (i.e. weight-lowering drugs or ovulation inducers) on BMI, ovulation, and/or hormonal profile in reproductive-aged women with overweight or obesity. We performed frequentist random-effect network meta-analyses and rated the certainty of the evidence. The primary outcomes were BMI and ovulation rate, and the secondary outcomes were serum reproductive hormone levels (gonadotrophins, androgens, or oestrogens). We performed sensitivity analyses, including the studies that only involved women with PCOS.\u0000\u0000\u0000OUTCOMES\u0000Among 1190 records screened, 148 full texts were assessed for eligibility resulting in 95 trials (9910 women), of which 53% presented a high or unclear risk of bias. The network meta-analyses revealed that, compared to control: diet combined with weight-lowering drugs (mean difference (MD) -2.61 kg/m2; 95% CI -3.04 to -2.19; τ2 = 0.22) and adding exercise (MD -2.35 kg/m2; 95% CI -2.81 to -1.89; τ2 = 0.22) led to the greatest decrease in BMI; exercise combined with diet and ovulation inducers (risk ratio (RR) 7.15; 95% CI 1.94-26.40; τ2 = 0.07) and exercise combined with diet and weight-lowering drugs (RR 4.80; 95% CI 1.67-13.84; τ2 = 0.07) produced the highest increase in ovulation rate; and exercise combined with diet and weight-lowering drugs was the most effective strategy in reducing testosterone levels (standardized mean difference (SMD) -2.91; 95% CI -4.07 to -1.74; τ2 = 2.25), the third most effective strategy in increasing sex hormone-binding globulin levels (SMD 2.37; 95% CI 0.99-3.76; τ2 = 2.48), and it was coupled with being ranked first in terms of free androgen index reduction (SMD -1.59; 95% CI -3.18 to 0.01; τ2 = 1.91). The surface under the cumulative ranking curve scores suggested that: diet combined with weight-lowering dr","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"47 S226","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Hydrogels with tunable mechanical plasticity regulate endothelial cell outgrowth in vasculogenesis and angiogenesis 作者更正:具有可调机械可塑性的水凝胶能在血管生成和血管生成过程中调控内皮细胞的生长
IF 16.6 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-16 DOI: 10.1038/s41467-024-47722-6
Zhao Wei, Meng Lei, Yaohui Wang, Yizhou Xie, Xueyong Xie, Dongwei Lan, Yuanbo Jia, Jingyi Liu, Yufei Ma, Bo Cheng, Sharon Gerecht, Feng Xu
{"title":"Author Correction: Hydrogels with tunable mechanical plasticity regulate endothelial cell outgrowth in vasculogenesis and angiogenesis","authors":"Zhao Wei, Meng Lei, Yaohui Wang, Yizhou Xie, Xueyong Xie, Dongwei Lan, Yuanbo Jia, Jingyi Liu, Yufei Ma, Bo Cheng, Sharon Gerecht, Feng Xu","doi":"10.1038/s41467-024-47722-6","DOIUrl":"https://doi.org/10.1038/s41467-024-47722-6","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"23 22‐23","pages":""},"PeriodicalIF":16.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants 作者更正:表皮生长因子受体的全面突变扫描揭示了细胞外结构域突变体对 TKI 的敏感性
IF 16.6 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-16 DOI: 10.1038/s41467-024-47675-w
T. Hayes, E. Aquilanti, N. Persky, Xiaoping Yang, Erica E Kim, Lisa Brenan, A. Goodale, Doug Alan, Ted Sharpe, Robert E Shue, Lindsay Westlake, Lior Golomb, Brianna R Silverman, Myshal D Morris, Ty Running Fisher, Eden Beyene, Yvonne Y Li, Andrew D Cherniack, F. Piccioni, J. K. Hicks, Andrew S Chi, Daniel P. Cahill, Jorg Dietrich, Tracy T Batchelor, D. Root, Cory M. Johannessen, Matthew Meyerson
{"title":"Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","authors":"T. Hayes, E. Aquilanti, N. Persky, Xiaoping Yang, Erica E Kim, Lisa Brenan, A. Goodale, Doug Alan, Ted Sharpe, Robert E Shue, Lindsay Westlake, Lior Golomb, Brianna R Silverman, Myshal D Morris, Ty Running Fisher, Eden Beyene, Yvonne Y Li, Andrew D Cherniack, F. Piccioni, J. K. Hicks, Andrew S Chi, Daniel P. Cahill, Jorg Dietrich, Tracy T Batchelor, D. Root, Cory M. Johannessen, Matthew Meyerson","doi":"10.1038/s41467-024-47675-w","DOIUrl":"https://doi.org/10.1038/s41467-024-47675-w","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"70 s313","pages":""},"PeriodicalIF":16.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Insights and implications of sexual dimorphism in osteoporosis 作者更正:骨质疏松症中性双态性的见解和影响
IF 12.7 3区 化学
ACS Combinatorial Science Pub Date : 2024-04-15 DOI: 10.1038/s41413-024-00329-5
Yuan-Yuan Zhang, Na Xie, Xiao-Dong Sun, Edouard C. Nice, Y. Liou, Canhua Huang, Huili Zhu, Zhisen Shen
{"title":"Author Correction: Insights and implications of sexual dimorphism in osteoporosis","authors":"Yuan-Yuan Zhang, Na Xie, Xiao-Dong Sun, Edouard C. Nice, Y. Liou, Canhua Huang, Huili Zhu, Zhisen Shen","doi":"10.1038/s41413-024-00329-5","DOIUrl":"https://doi.org/10.1038/s41413-024-00329-5","url":null,"abstract":"","PeriodicalId":14,"journal":{"name":"ACS Combinatorial Science","volume":"84 5","pages":""},"PeriodicalIF":12.7,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书